GE Healthcare Develops Technologies to Enable Effective Drug Discovery
Complete the form below to unlock access to ALL audio articles.
GE Healthcare, a unit of General Electric Company has announced that it has showcased at the Society for Biomolecular Screening’s (SBS) 11th Annual Conference three advanced technologies currently in development that will help scientists understand disease, research fundamental biological processes, and discover therapeutic agents.
“GE Healthcare is a leading global provider of drug discovery systems, products and services,” said Keiko Hattori, Senior Vice President for Discovery Systems at GE Healthcare.
“These latest developments demonstrate GE Healthcare’s commitment to providing innovative tools for our customers working in biomolecular discovery and disease research.”
“We strive to help researchers continually improve their drug discovery and development processes.”
GE has highlighted Micronucleus, software application for GE Healthcare’s IN Cell Analyzer 1000 and 3000 screens for genotoxicity in potential drug compounds and helps to eliminate toxic compounds early in the drug discovery and development process.
The micronuclei assay is designed to identify genotoxicity by finding breaks in DNA and is one of the most critical assays in the FDA approval process for drugs.
Within 10 minutes or less, the Micronucleus software application can analyze a 96 well plate when used with the IN Cell Analyzer 3000.
The software further enhances IN Cell Analyzer’s automated analysis capabilities to observe cells in culture during research to help build a picture of cell behavior and responses.
The Optical Z-sectioning module for the IN Cell Analyzer 1000 is designed to extend the high image quality obtained in cellular assays to imaging of tissue sections.
This development is a combination of hardware and proprietary software control that is designed to remove out-of-focus light above and below the focal plane.
This will allow researchers to benefit from high quality 2D and 3D images of fluorescently labelled cellular and tissue samples for analysis.
The Adenoviral Vector Gene Delivery System is designed to expand the possibilities for lead compound profiling and drug target validation by enabling the development of cellular assays that can aid secondary screening and early-stage drug discovery.
The system includes a range of ready-to-use recombinant adenoviral preparations.
Each preparation contains the gene encoding a protein target fused to EGFP or emerald FP, or a response element controlling the _expression of nitroreductase (NTR).
“The right solutions can help researchers increase efficiency and reduce cost to more accurately develop drugs that positively impact patient lives,” said Hattori.
“At SBS GE Healthcare is showcasing our proven solutions as well as our advanced technologies for the future.”
